Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers
About this study
The objective of this project is to determine in a non-invasive manner (fecal samples) the predictive value of the intestinal microbiota and the presence of genotoxin-producing bacteria on the response to neoadjuvant treatment in rectal cancer. This could lead to a better understanding and selection of patients for personalized treatment in rectal cancer.
- Condition
- Rectal Cancer
- Tested
- Biological collection
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Rectal Cancer
- Histologically proven lower and mid-rectal adenocarcinoma at clinical stage II and III
- Patient is to receive neoadjuvant treatment (radiochemotherapy or chemotherapy or radiotherapy). Induction chemotherapy such as folfox or folfirinox is allowed
- Patient who has signed the informed consent of the study
- Male or female ≥ 18 years old
- Appropriate contraceptive measures should be used by both men and non-menopausal women before entering the trial until at least 8 weeks after the last course of radiochemotherapy. The investigator should inform the patient about the contraceptive measures to be used.
Exclusion 9
- Antibiotic treatment at the time or in the month preceding stool sampling
- Presence of an ostomy
- Previous treatment for rectal cancer
- Patient not affiliated to a French social protection system
- Patient not in favour of good compliance with treatment for psychological, family, social or geographical reasons
- Legal incapacity (Patient under curatorship or guardianship)
- Prior radiation therapy or pelvic curia in the year prior to inclusion
- History of other cancers in the last 5 years (except for in-situ cervical carcinomas and non-melanoma skin carcinomas treated optimally)
- Pregnant or breastfeeding woman
Where
2 sites, 2 recruiting
Institut régional du Cancer de Montpellier
Montpellier, Hérault, France
CHU Clermont-Ferrand
Clermont-Ferrand, Puy De Dôme, France
Contact
-
Aurore MOUSSION, MD
0467612446 Aurore.Moussion@icm.unicancer.fr
Potential match only. Final eligibility is determined by the study team.